Trial Profile
Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 10 Mar 2017 Status changed from not yet recruiting to completed.
- 27 May 2015 New trial record